Published in final edited form as:

Mol Pharmacol. 2008 October ; 74(4): 990–999. doi:10.1124/mol.108.048637.

Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity

Namandjé N. Bumpus and Paul F. Hollenberg

Department of Pharmacology, University of Michigan, Ann Arbor, Michigan

Abstract

Human P450 2B6 is a polymorphic enzyme involved in the oxidative metabolism of a number of clinically relevant substrates. The lysine 262 to arginine mutant of P450 2B6 (P450 2B6.4) has been shown to have differential effects on P450 2B6 catalytic activity. We previously reported that the mutant enzyme was not able to metabolize 17- α -ethynylestradiol (17EE) or become inactivated by 17EE or efavirenz, which are inactivators of the wild-type enzyme. Studies were performed to elucidate the mechanism by which this mutation affects P450 2B6 catalytic activity. Studies using phenyldiazene to investigate differences between the active site topologies of the wild-type and mutant enzymes revealed only minor differences. Similarly, K_s values for the binding of both benzphetamine and efavirenz were comparable between the two enzymes. Using the alternate oxidant *tert*-butyl hydroperoxide, the mutant enzyme was inactivated by both 17EE and efavirenz. The stoichiometry of 17EE and efavirenz metabolism by P450s 2B6 and 2B6.4 revealed the mutant enzyme was more uncoupled, producing hydrogen peroxide as the primary product. Interestingly, the addition of cytochrome b_5 improved the coupling of the mutant, resulting in increased catalytic activity. In the presence of cytochrome b_5 the variant readily metabolized 17EE and was inactivated by both 17EE and efavirenz. It is therefore proposed that the oxyferrous or iron-peroxo intermediate formed by the mutant enzyme in the presence of 17EE and efavirenz may be less stable than the same intermediates formed by the wild-type enzyme.

INTRODUCTION

The cytochromes P450 (P450) are a superfamily of heme-containing monooxygenases that catalyze the oxidative metabolism of a number of endogenous and exogenous compounds, including clinically relevant drugs, pesticides and carcinogens. The P450 catalytic cycle consists of a number of steps including: substrate binding to ferric P450; reduction, as a result of the transfer of an electron from NADPH via NADPH-cytochrome P450 reductase (reductase); binding of molecular oxygen to ferrous P450, leading to the formation of oxyferrous P450; transfer of a second electron to oxyferrous P450 from NADPH via reductase, or in some instances cytochrome b_5 ; formation of the oxygenating species; and subsequent oxidation of the substrate followed by product release. In addition, hydrogen peroxide can be formed via the decomposition of the oxyferrous complex or by autooxidation of the two-electron reduced P450 (Oprian et al., 1983). This phenomenon is referred to as “uncoupling”.

Human P450 2B6 plays a major role in the metabolism of a growing list of compounds including bupropion, an anti-depressant and smoking cessation aid; efavirenz, a non-nucleoside HIV-1 reverse transcriptase inhibitor; and cyclophosphamide, a chemotherapeutic prodrug that requires metabolic activation (Roy et al., 1999; Faucette et al., 2000; Hesse

et al., 2000; Ward et al., 2003). Certain substrates of P450 2B6 such as efavirenz are also mechanism-based inactivators of the enzyme. Mechanism-based inactivation occurs when a substrate, in the process of metabolism, is converted to a reactive intermediate that binds covalently to the active site of the P450, rendering it inactive. A number of single nucleotide polymorphisms have been found in the *P450 2B6* gene (Lang et al., 2001). Recent studies in patients have demonstrated that some of these mutations can have significant effects on clinical outcomes (Tsuchiya et al., 2004; Wang et al., 2006). However, studies investigating the mechanisms underlying these effects are lacking. In order to address this issue, we have used recombinant P450 2B6 and a mutant P450 2B6 K262R (2B6.4), which corresponds to the *P450 2B6**4 variant allele observed in humans (785A>G, exon 5), to investigate the functional consequences of this amino acid mutation. This mutant is of particular interest because it is present in a number of P450 2B6 variant alleles and, therefore, has a high mutation frequency.

Previously, we demonstrated that efavirenz and 17EE (Figure 1), which both inactivate P450 2B6 in the reconstituted system, do not inactivate P450 2B6.4 (Bumpus et al., 2005; Bumpus et al., 2006). Further, in those studies the mutant enzyme was not able to metabolize 17EE, a substrate readily metabolized by the wild-type enzyme. In this study, we have systematically investigated some of the aspects of P450 catalytic function that could potentially be altered by the K262R mutation. Therefore, we conducted studies to elucidate whether differences in the catalytic activities of P450 2B6 and P450 2B6.4 are related to: 1) active site topology; 2) substrate binding; 3) interaction with reductase; 4) reaction coupling. Our approach included the use of phenyldiazene to probe the active site of the P450, and the use of an alternate oxidant to support catalytic activity in the absence of reducing equivalents from NADPH. The results presented here suggest that there may be some differences in the active site topologies of the two enzymes, although the binding constants derived from spectral binding studies were similar. Interestingly, reaction stoichiometry experiments revealed that the reactions catalyzed by the mutant were more uncoupled than the reactions catalyzed by the wild-type enzyme. The addition of cytochrome b₅ improved the coupling of P450 2B6.4 and facilitated inactivation of the enzyme by both compounds.

MATERIALS AND METHODS

Materials

Benzphetamine, BSA, 17EE, catalase and NADPH were purchased from Sigma (St. Louis, MO). Efavirenz was purchased from Toronto Research Chemicals (Ontario, Canada). 7-Ethoxy-4-(trifluoromethyl)coumarin (7-EFC) was obtained from Molecular Probes (Eugene, OR). Phenyldiazene was purchased from Research Organics (Cleveland, OH). The P450 2B6 plasmid was a generous gift from Dr. James Halpert, University of Texas Medical Branch, Galveston, Texas. All other chemicals were of the highest grade commercially available.

Site-Directed Mutagenesis, Expression and Purification of P450s and Reductase

Construction of the P450 2B6.4 mutant was performed as described by Bumpus et al. (Bumpus et al., 2005). P450 2B6, P450 2B6.4, and NADPH-P450 reductase were expressed in *E. coli* Topp 3 cells and purified according to published protocols (Hanna et al., 1998; Hanna et al., 2000; Scott et al., 2001). Cytochrome b₅ was purified from liver microsomes of phenobarbital-treated Long-Evans rats.

N-phenylprotoporphyrin IX Regioisomer Formation

The procedures used in these studies was adapted from published protocols (Swanson et al., 1991; Tuck et al., 1992). The phenyldiazene stock used in these experiments was prepared by adding 2.5 μ l of neat phenyldiazene to 200 μ l of 1N KOH. For the myoglobin experiments, 5 nmol of myoglobin in 100 mM KPi, pH 7.4, was placed into a 1 ml cuvette and the absorbance

spectrum from 400 to 500 nm was recorded. Then, 3 μ l of the phenyldiazene stock was added to the cuvette and the absorbance spectrum was once again determined. A peak was observed at 430 nm, which is characteristic of a myoglobin phenyl-iron complex. Once the peak reached a maximum (approximately 10 min), the protein was denatured by adding the contents of the cuvette to 5 ml of 5% sulfuric acid (aq). After sitting for 2 hours the sample was extracted twice with an equal volume of methylene chloride. The extract was then dried down under a stream of nitrogen. For the P450 experiments, 2 nmol of P450 in 100 mM KPi, pH 7.4, was placed into a 1 ml cuvette and the absorbance from 400–500 nm was measured. Then, 1.5 μ l of the phenyldiazene stock solution was added to the cuvette and peak formation at 478 nm was monitored. After the peak formation reached a maximum (approximately 10 min), 3 μ l of potassium ferricyanide [50 μ M] was added to the cuvette and the contents of the cuvette were mixed and allowed to sit for 3 minutes. This was repeated twice to induce migration of the phenyl group from the iron to the porphyrin nitrogens. The sample was then denatured and extracted with methylene chloride as described above for myoglobin. After being dried under nitrogen, the *N*-phenylprotoporphyrins were reconstituted in 150 μ l of solvent A (40% water, 59.5% methanol, .5% acetic acid). The samples were analyzed by HPLC LC-MS using a Phenomenex phenyl-hexyl column under isocratic conditions with 70% A and 30% B (99.5% methanol, .5% acetic acid). The area under the curve was determined for each of the four resulting regioisomers. These data were then expressed as a percentage of the total sum of the areas under the curve of all four peaks.

Spectral Binding

Spectral binding experiments were performed by titrating 1 μ M of P450s 2B6 and 2B6.4 with either benzphetamine (dissolved in water) or efavirenz (dissolved in ethanol) at room temperature. Samples were brought to a total volume of 1 ml using 100 mM KPi, pH 7.4, and placed into a cuvette. The reference cuvette also contained 1 μ M of the P450s in 100 mM KPi, pH 7.4. Vehicle solvent was added to the reference cuvette immediately following the titration of either benzphetamine or efavirenz into the sample cuvette. UV-visible spectra were recorded from 350–500 nm following the addition of each aliquot of the ligand to the sample cuvette and an equal volume of the vehicle solvent to the reference. The absorbance differences between the maximum and minimum absorbencies observed in the difference spectrum following each addition were recorded and plotted against the concentrations of benzphetamine or efavirenz added using GraphPad Prism (GraphPad software, San Diego, CA). Spectral binding studies to determine the apparent K_d of reductase binding to P450 were performed in a similar fashion by titrating 1 μ M P450 with reductase (0–8 μ M) as previously described by French et al., (French et al., 1980). The K_s for benzphetamine or efavirenz binding and the apparent K_d values for reductase binding were approximated by plotting the inverse of the absorbance changes between 390 nm and 420 nm (type I) versus the inverse of the concentrations of either benzphetamine or reductase, and the inverse of the changes between 436 nm and 416 versus the inverse of the efavirenz concentrations.

Alternate oxidant studies

The alternate oxidant *tert*-butyl hydroperoxide (*t*BHP) was used to support P450 catalytic activity in place of NADPH, reductase and molecular oxygen. P450s 2B6 or 2B6.4 were placed in 50 mM KPi, pH 7.4, and diluted to a final volume of 200 μ l. Following a 5 min pre-incubation of the P450 with *t*BHP and inactivator, an aliquot (12 μ l) of this primary mixture was transferred into 990 μ l of assay mixture that contained 100 μ M 7-EFC and 40 μ g BSA/ml in 50 mM potassium phosphate buffer, pH 7.4. The assays were performed as previously described (Sridar et al., 2005). The concentration of *t*BHP (2.5 mM) used in experiments to test for inactivation was determined to be optimal by measuring 7-EFC *O*-deethylation activity at concentrations of *t*BHP ranging from 0 to 5 mM. The presence of 2.5 mM *t*BHP resulted in

maximum formation of the 7-EFC *O*-deethylated product, with no measurable inactivation of the enzyme.

Reaction Stoichiometry

P450 2B6 or P450 2B6.4 (65 pmol) was incubated with reductase at a 1:2 molar ratio of P450:reductase for 45 min at 4°C. In the experiments in the presence of cytochrome b₅, samples were reconstituted in a 1:2:1 molar ratio of P450:reductase:cytochrome b₅. P450 and reductase were incubated together on ice for 5 min prior to the addition of cytochrome b₅. The sample was brought to a total volume of 1 ml using 100 mM potassium phosphate buffer, pH 7.4 and placed into a cuvette. The sample was allowed to sit at room temperature for 3 min before the addition of NADPH to a final concentration of 200 μM. NADPH consumption was measured continuously, both in the presence and absence of substrate (10 μM 17EE or efavirenz), by monitoring the absorbance at 340 nm over 4 min. The concentration of NADPH was determined using an extinction coefficient of 6.22 mM⁻¹cm⁻¹ (Gorsky et al., 1984). To measure product formation, 700 μl of the sample was removed and the reaction was quenched by the addition of 300 μl of acetonitrile. Since the metabolism of both efavirenz and 17EE leads to the formation of multiple products, substrate depletion was used to quantify product formation, 700 μl of the sample was removed and the reaction was quenched by the addition of 300 μl of acetonitrile. Since the metabolism of both efavirenz and 17EE leads to the formation of multiple products, substrate depletion was used to quantify product formation. For this reason substrate concentrations were used where depletion could be readily determined. The samples were analyzed by HPLC as previously described (Kent et al., 2002; Bumpus et al., 2006). The remaining 300 μl of the sample was used to determine the amount of hydrogen peroxide formed using the ferrithiocyanate method (Hildebrandt et al., 1978). Excess water formed as a result of the 4-electron reduction of oxygen by two units of NADPH was estimated using the following equation: $H_2O = (NADPH - (Product + H_2O_2))/2$.

Inactivation of P450 2B6.4 in the presence of cytochrome b₅

The purified P450 was reconstituted with reductase and cytochrome b₅ as described above for 45 minutes at 4 °C. The primary reaction mixtures contained 1 μM P450, 2 μM reductase, 1 μM cytochrome b₅, 110 U catalase and efavirenz (0–50 μM) or 17EE (0–160 μM) in 50 mM potassium phosphate buffer, pH 7.4. The primary reaction mixtures were then incubated for 10 min at 30 °C prior to the addition of NADPH to a final concentration of 1.2 mM. Following the initiation of the reaction by the addition of NADPH, 12 μL aliquots were removed from the primary reaction mixtures at the times indicated and transferred to 990 μL of the secondary reaction mixtures which contained 100 μM 7-EFC, 1 mM NADPH, and 40 μg BSA/mL in 50 mM potassium phosphate buffer, pH 7.4. The secondary reaction mixtures were incubated for 10 min at 30 °C, and then quenched by the addition of 334 μL of acetonitrile. The amount of 7-hydroxy-4-(trifluoromethyl) coumarin formed was measured at room temperature using an excitation wavelength of 410 nm and an emission wavelength of 510 nm on a RF-5310 Spectrofluorophotometer (Shimadzu Scientific Instruments, Inc., Wood Dale, IL).

17EE Metabolism

P450 2B6.4 was reconstituted together with reductase and cytochrome b₅ as described above. The primary reaction mixture contained 1 μM P450, 2 μM reductase, 1 μM reductase, 1 μM cytochrome b₅, 200 μg/ml ascorbate, 110 U catalase, 40 μM 17EE and 50 mM potassium phosphate buffer, pH 7.4. The metabolites were resolved by reverse-phase HPLC according to a published protocol (Kent et al., 2002).

RESULTS

P450 2B6 and P450 2B6.4 active site topology

Phenyldiazene forms a σ -bonded complex with the heme iron of the P450, resulting in the formation of a phenyl-iron complex. Oxidation of the iron facilitates the migration of the phenyl group to an available pyrrole nitrogen belonging to rings A, B, C or D. The ratio of formation of the resulting N-protoporphyrin IX regioisomers, denoted as N_A, N_B, N_C and N_D, allow for inferences to be made regarding the accessibility of each of the four pyrrole rings (Swanson et al., 1991; Tuck et al., 1992; Yamaguchi et al., 2004). Phenyldiazene was added to P450s 2B6 and 2B6.4, and the formation of the phenyl-iron complex was determined spectrally by monitoring the peak formation at 478 nm and the concomitant decrease at 418 nm (data not shown). Following oxidation using ferricyanide, the samples were analyzed by LC-MS and all four N-phenylprotoporphyrin IX regioisomers were observed. The elution times of the resulting regioisomers were compared to the standards produced from the incubation of phenyldiazene with myoglobin (data not shown). The major product formed by the wild-type enzyme was N_C, which accounted for $46 \pm 2\%$ of the total regioisomer formation. N_A, N_B and N_D were also detected, and accounted for $10 \pm .7\%$, $7 \pm .5\%$ and $37 \pm 1\%$ respectively (Figure 2). Interestingly, there were some differences observed between the mutant and the wild-type enzyme. The reaction of phenyldiazene with P450 2B6.4 also resulted in the formation of all four N-phenylprotoporphyrin IX regioisomers (Figure 3). However, N_C only represented $37 \pm 1\%$ of the overall formation, while N_A, N_B and N_D constituted $15 \pm .5\%$, $11 \pm 3\%$ and $38 \pm 4\%$, respectively. These data suggest that there may be differences in the active site topologies of the two enzymes.

Spectral binding of benzphetamine and efavirenz to P450 2B6 and P450 2B6.4

Spectrophotometric titrations were performed to investigate whether these two substrates of P450 2B6 and P450 2B6.4 showed differences in binding affinity to the two enzymes. The dissociation constants (K_s) were determined from the titration curves. Benzphetamine was chosen because it produces a prominent type I spectral change in P450 2B6. Efavirenz caused a type II spectral change, which is characteristic of a nitrogen atom coordinating to the heme. Both enzymes showed similar affinities for both of the substrates. The K_s values for benzphetamine binding to P450s 2B6 and 2B6.4 were $18 \mu\text{M} \pm 0.7$ and $17 \mu\text{M} \pm 0.4$, respectively. The efavirenz spectral dissociation constants were also similar between the two enzymes, with a value of $85 \pm 2.3 \mu\text{M}$ for the wild-type enzyme and $123 \pm 3.1 \mu\text{M}$ for the variant enzyme. The maximum ΔA values were similar in all cases. The K_s values of 17EE binding could not be determined since 17EE does not induce measurable spectral shifts. These data on the binding of benzphetamine and efavirenz suggest that P450 2B6 and P450 2B6.4 are able to bind substrates in a similar manner. Therefore, the differences in catalysis may not be directly related to substrate binding.

Inactivation of P450s by 17EE and efavirenz using an alternate oxidant

We used *tert*-butyl hydroperoxide as an activated oxygen surrogate to investigate whether the wild-type and/or mutant enzymes could become inactivated by 17EE or efavirenz in a reductase and electron-free system. *t*BHP produces an active iron-oxygen species with the P450 that can support P450 catalytic activity in the absence of molecular oxygen and reducing equivalents from NADPH (White and Coon, 1980). Since peroxides by themselves have the ability to inactivate P450s, we tested a range of *t*BHP concentrations to ensure that the inactivation we were measuring was indeed due to the compounds being investigated. Ultimately, the concentration that we chose did not exhibit any measurable inhibitory effect on the activity of the enzyme in incubations ranging from 0–20 min. Further, the values reported here for inactivation of both enzymes in the presence of 17EE and efavirenz is expressed as a percentage of the activity detected in the presence of *t*BHP alone. Therefore, the activity in the presence

of the peroxide alone was considered to be 100% and was comparable to activity that would be expected using the NADPH-requiring reductase system. Both P450 2B6 and P450 2B6.4 were inactivated by 17EE and efavirenz when *t*BHP was used as an oxidant. P450 2B6 7-EFC *O*-deethylation activity remaining was $52 \pm 2\%$ when the concentration of efavirenz was 50 μM and $32 \pm 1\%$ when incubated with 80 μM efavirenz (Table 1). P450 2B6 was also inactivated by 17EE in the presence of *t*BHP in a concentration-dependent manner (Table 1). Interestingly, *t*BHP was also able to support the inactivation of P450 2B6.4 by both compounds, though it does appear that the mutant enzyme is less susceptible to inactivation by 17EE when compared to the wild-type enzyme (Table 1). Thus, in a system that is not dependent upon reductase, NADPH and oxygen, the variant enzyme behaved in a manner similar to the wild-type enzyme. These data suggest that the ability of P450 2B6.4 to interact with reductase may be compromised.

Determination of the apparent K_d of reductase binding to P450s 2B6 and 2B6.4

To determine whether the lack of inactivation of the mutant enzyme by 17EE and efavirenz in the reconstituted system was the result of impaired interaction with reductase, complex formation of the P450s with reductase was measured spectrophotometrically. The binding of reductase to P450s results in a low to high spin shift in the heme iron, characterized spectrally by a decrease in the absorbance at 418 nm and an increase in the absorbance at 385 nm (French et al., 1980). The apparent K_d for the interaction of the reductase with P450 2B6.4 (918 nM) was almost 4-fold greater than the value obtained from experiments with the wild-type enzyme (240 nM). This difference does not seem to be marked enough to solely account for the differences in catalytic activity we observed between the two enzymes since we routinely used reductase concentrations in excess of P450. To gain a more complete understanding of the catalytic activities of the two enzymes, the reaction stoichiometry for the metabolism of 17EE and efavirenz by P450 2B6 and P450 2B6.4 was determined.

Reaction stoichiometry

As shown in Table 2, NADPH consumption was not increased by the presence of substrate when measured for either of the enzymes. During the metabolism of 17EE and efavirenz by P450 2B6, hydrogen peroxide was formed at a rate similar to the rate of product formation. In contrast, the majority of NADPH consumed by P450 2B6.4 resulted in the formation of hydrogen peroxide (Table 2). These data indicate that the metabolic reactions of P450 2B6.4 with 17EE and efavirenz are more uncoupled than the metabolism of these compounds by P450 2B6.

Several studies have demonstrated that cytochrome b_5 can increase the coupling of P450 catalyzed reactions, including those involving P450 2B enzymes (Gruenke et al., 1995; Perret and Pompon, 1998). With this in mind, we measured NADPH consumption, hydrogen peroxide formation and product formation in the presence of cytochrome b_5 . Reconstitution of P450 2B6.4 with cytochrome b_5 as well as reductase dramatically improved the coupling of both reactions (Table 3). Interestingly, cytochrome b_5 only had a minimal effect on the coupling of the wild-type reactions (Table 3). Further, P450 2B6.4-mediated 17EE product formation, as measured by substrate depletion, was observed when cytochrome b_5 was present in the reconstitution mixture (Table 3). In light of these findings, we went on to test whether inactivation of P450 2B6.4 by efavirenz and 17EE could occur in the presence of cytochrome b_5 .

Inactivation of P450 2B6.4 by 17EE and efavirenz in the presence of cytochrome b_5

We previously reported that P450 2B6.4 is not inactivated by 17EE and efavirenz when reconstituted with reductase alone (Bumpus et al., 2005; Bumpus et al., 2006). Inactivation of the mutant enzyme by 17EE and efavirenz in the presence of cytochrome b_5 was measured

using the 7-EFC *O*-deethylation assay. P450 2B6.4 was inactivated by efavirenz (Figure 4) and 17EE (Figure 5) in a time- and concentration-dependent manner and the inactivation exhibited an absolute requirement for NADPH. The activity loss followed pseudo first order kinetics. Linear regression analysis was performed and the kinetic constants for the efavirenz-mediated inactivation of the mutant enzyme were determined from the insets in figures 4 and 5. The K_I values for inactivation of P450 2B6.4 by efavirenz and 17EE were 30 μ M and 113 μ M respectively. We have previously observed K_I values for the wild-type 2B6 of 20 μ M for efavirenz-mediated inactivation (Bumpus et al., 2006) and 10 μ M for inactivation by 17EE (data not shown).

Metabolism of 17EE by P450 2B6.4 requires cytochrome b₅

Studies were conducted to determine which 17EE metabolites were formed during metabolism by P450 2B6.4 in the presence of cytochrome b₅. 17EE was incubated with P450 2B6.4 that was reconstituted with reductase and cytochrome b₅ in the presence or absence of NADPH. The metabolites were analyzed using reverse phase HPLC as shown in Figure 6. P450 2B6.4 metabolized 17EE to give a number of major metabolites denoted as C, D and E as well as a minor metabolites, A₁, A₂ and B. Metabolites D and E have been identified as estrone and 2-hydroxy-17EE, respectively. To date, the structures of metabolites A₁, A₂, B, C have yet to be elucidated, however, LC/MS mass-to-charge ratios of 528, 451, 451 and 456 have been determined for these metabolites, respectively. Metabolite C is only present under conditions where inactivation is observed, suggesting that this metabolite may play a critical role in the inactivation of the P450 by 17EE (Kent et al., 2002). Overall metabolite formation by the mutant enzyme was approximately 10-fold lower than what we previously observed for the wild-type enzyme. The ratios of formation for each of the metabolites were similar between the two enzymes, although metabolite B was not present in the profiles for the wild-type enzyme observed in our previous studies (Kent et al., 2002; Bumpus et al., 2005).

DISCUSSION

We have previously demonstrated that the mutation of lysine 262 of the P450 2B6 protein to arginine can result in marked changes in catalytic activity (Bumpus et al., 2005; Bumpus et al., 2006). Our findings that P450 2B6.4 was not inactivated by efavirenz and 17EE, known inactivators of the wild-type enzyme, were the most intriguing (Bumpus et al., 2005). Additional studies performed in our lab have demonstrated that differences in catalytic activity between the two enzymes are not limited to efavirenz and 17EE since phencyclidine, a well-characterized inactivator of wild-type P450 2B6, also does not inactivate P450 2B6.4 (Shebley and Hollenberg, 2007).

Previous studies using a number of P450s have demonstrated that phenyldiazene is a useful tool for gaining information about the topology of the P450 active site (Dierks et al., 1998; Schrag and Wienkers, 2000; Yamaguchi et al., 2004). In the case of certain P450 isoforms including bacterial P450s and P450 3A4, the information gained using phenyldiazene has been consistent with X-ray crystallography data (Ortiz de Montellano, 1995; Yamaguchi et al., 2004). In the present study, we used phenyldiazene to investigate whether the K262R mutation leads to significant changes in active site topology. Although the overall profiles for the formation of the regioisomers were similar between the two enzymes, there was a difference in the migration of the phenyl group to the nitrogen of the pyrrole ring C. In the experiments with the wild-type enzyme, the N_C regioisomer accounted for 46% of the total formation. However, in the case of the mutant, N_C formation only accounted for 37% of the total. Though this difference is small, it suggests that the active site topologies of the two enzymes differ to some extent. Subsequent spectral binding studies using benzphetamine and efavirenz as

substrates revealed that the binding of these two substrates were similar between the two enzymes, suggesting that the K262R mutation does not significantly affect binding.

According to the P450 2B4 crystal structure, the only structure of a P450 2B family member currently available, residue 262 is in the G/H loop (Scott et al., 2003; Scott et al., 2004). Although this region is not in close proximity to the active site, it could potentially play a role in the interaction with reductase. To test whether the K262R mutation alters the ability of the enzyme to interact with reductase, we performed experiments to measure the ability of each P450 to associate with reductase. These studies suggested that the mutant may have a somewhat lower affinity for reductase, however, the difference between the mutant and wild-type enzymes in reductase binding did not seem profound enough to account for the marked differences in catalytic activity. In addition, we used *t*BHP as an oxidant to determine if the mutant enzyme would be catalytically similar to the wild-type in the absence of the requirement to interact with reductase. Interestingly, in the presence of alternate oxidants the mutant was readily inactivated by 17EE and efavirenz suggesting that electron transfer to P450 2B6.4 may be compromised during these reactions when using the reconstituted system.

In order to gain a comprehensive understanding of a particular reaction it is necessary to determine the stoichiometry of the reaction. Investigation of the stoichiometry for metabolism of 17EE and efavirenz by the two enzymes indicated that the mutant appeared to be more uncoupled. Coupling can be defined by the percentage of electrons from NADPH used towards the formation of monooxygenated metabolites. Therefore, uncoupling refers to a decrease in monooxygenated metabolite formation and a concomitant increase in non-productive metabolite product formation. This can occur as a result of the autooxidation of the oxyferrous P450 to superoxide which is ultimately converted to hydrogen peroxide, as well as from the release of hydrogen peroxide from the peroxo-iron intermediate. Further, “excess” water can be produced from the 4-electron reduction of oxygen by two molecules of NADPH. Reaction stoichiometry relates NADPH and oxygen consumption with hydrogen peroxide and metabolite formation. Interestingly, the rate of NADPH consumption by each of the enzymes was similar in both the presence and absence of substrate. In the absence of substrate, the major product formed by the wild-type enzyme was water, while hydrogen peroxide formation was favored by the mutant enzyme. This suggests that P450s 2B6 and 2B6.4 are highly uncoupled enzymes and that in the absence of substrate they may function as NADPH oxidases and proceed through the catalytic cycle resulting in the formation of the shunted products hydrogen peroxide and water. In an attempt to improve the coupling of the P450 2B6.4 reactions, cytochrome *b*₅ was added to the reconstitution mixture. The presence of cytochrome *b*₅ improved the coupling of the mutant enzyme, and the hydrogen peroxide levels were closer to those observed for the reactions catalyzed by the wild-type enzyme. However, the rate of water formation by both enzymes was similar in both the presence and absence of cytochrome *b*₅, suggesting that cytochrome *b*₅ preferentially affected the shunt pathway leading to H₂O₂ formation. Further, the addition of cytochrome *b*₅ to the reconstitution mixture resulted in the inactivation of P450 2B6.4 by efavirenz and 17EE and the ability of the enzyme to metabolize 17EE to generate a number of products.

The precise mechanism by which cytochrome *b*₅ acts upon certain P450s remains unknown, though it has been shown to increase, inhibit or have no effect on P450 activity depending upon the P450 isoform and the substrate being investigated (Schenkman and Jansson, 2003). There are two primary hypotheses to explain the stimulatory effect of cytochrome *b*₅ on some P450-mediated reactions. The first is that reduced cytochrome *b*₅ donates the second electron in the catalytic cycle to the P450 (Yamazaki et al., 2001; Yamazaki et al., 2002; Zhang et al., 2005). This is supported by studies showing electron transfer from cytochrome *b*₅ to P450 as well as the observation that “uncoupling” is decreased in the presence of the *b*₅ protein (Perret and Pompon, 1998). In this instance, the presence of cytochrome *b*₅ results in a decrease in

hydrogen peroxide formation and a subsequent increase in product formation, possibly by stabilizing the oxyferrous P450 complex, leading to a decrease in release of superoxide (Perret and Pompon, 1998). Interestingly, studies performed by Zhang et al., under single turnover conditions demonstrate that cytochrome *b*₅ and reductase reduce oxyferrous P450 (in this case P450 2B4) at a similar rate, although catalysis occurs faster in the presence of cytochrome *b*₅ (Zhang et al., 2003). To explain this phenomenon, the authors hypothesize that the conformation of the oxyferrous P450 may be different in the presence of cytochrome *b*₅ and reductase leading to more rapid catalysis though the rate of reduction is the same. The second hypothesis is that cytochrome *b*₅ physically interacts with the P450 causing a conformational change that facilitates interaction with the substrate or reductase. This notion is supported by studies where the apo-cytochrome *b*₅, which cannot be reduced and donate the second electron, was able to stimulate P450-catalyzed reactions (Yamazaki et al., 1996). In our studies, cytochrome *b*₅ improved the coupling of the mutant enzyme, facilitating metabolism of 17EE by the mutant and inactivation by both 17EE and efavirenz. Further, we performed studies using both apo-cytochrome *b*₅ and Mn-cytochrome *b*₅, which cannot act as electron donors, and did not see any improvement in the catalytic activity of P450 2B6.4 (data not shown). With these data in mind, we propose that cytochrome *b*₅ may act in our system by stabilizing the oxyferrous P450 2B6.4 in the presence of 17EE and efavirenz, as evidenced by a decrease in hydrogen peroxide formation and increase in product formation. The fact that the rate of water formation, which occurs later in the cycle, was not affected by cytochrome *b*₅ lends more support to this notion. However, we cannot rule out the possibility that oxyferrous P450 2B6.4 may exist in a different conformation in the presence of 17EE and efavirenz when compared to the wild-type. Though the exact molecular mechanism underlying the differences between these two enzymes remains to be elucidated, the studies reported here have provided evidence that the stability and/or conformation of the oxyferrous intermediate may play a role. In addition, it is possible that multiple mechanisms may be involved since the presence of cytochrome *b*₅ did not result in P450 2B6.4-mediated metabolism of 17EE comparable to that of the wild-type. Further studies to elucidate the precise mechanism by which cytochrome *b*₅ increases the catalytic activity of P450 2B6.4 could potentially include measuring the formation and stability of the oxyferrous complex of P450 2B6.4 versus P450 2B6.

In summary, we have investigated the effects of the K262R mutation on active site topology, substrate binding, interaction with reductase and reaction stoichiometry. The inactivation of P450 2B6.4 by efavirenz and 17EE showed an absolute requirement for cytochrome *b*₅. In the presence of cytochrome *b*₅, the reactions catalyzed by the mutant enzyme exhibited improved coupling. These studies provide evidence that the differences in the catalytic properties of P450 2B6 and P450 2B6.4 are related to uncoupling of P450 2B6.4 mediated metabolism.

ACKNOWLEDGEMENTS

We thank Hsia-lien Lin for expression and purification of reductase and Dr. Kate Noon for thoughtful discussions and suggestions regarding the phenyldiazene experiments.

This study was supported in part by a grant from the National Cancer Institute, National Institutes of Health (CA 16954) (P.F.H.), T32 GM007767 and a predoctoral fellowship in pharmacology/toxicology from the PhRMA Foundation (N.N.B.).

Abbreviations

P450, cytochrome P450; P450 2B6.4, P450 2B6 Lysine 262 Arginine mutant; 17EE, 17- α -ethynylestradiol; 7-EFC, 7-ethoxy-4-(trifluoromethyl)coumarin; *t*BHP, *tert*-butyl hydroperoxide; HPLC, high-performance liquid chromatography; LCMS, liquid-chromatography mass-spectrometry; ESI, electrospray ionization..

REFERENCES

- Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. *J Pharmacol Exp Ther* 2006;318:345–351. [PubMed: 16611850]
- Bumpus NN, Sridar C, Kent UM, Hollenberg PF. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. *Drug Metab Dispos* 2005;33:795–802. [PubMed: 15769884]
- Dierks EA, Zhang Z, Johnson EF, de Montellano PR. The catalytic site of cytochrome P450A11 (CYP4A11) and its L131F mutant. *J Biol Chem* 1998;273:23055–23061. [PubMed: 9722531]
- Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. *Drug Metab Dispos* 2000;28:1222–1230. [PubMed: 10997944]
- French JS, Guengerich FP, Coon MJ. Interactions of cytochrome P-450, NADPH-cytochrome P-450 reductase, phospholipid, and substrate in the reconstituted liver microsomal enzyme system. *J Biol Chem* 1980;255:4112–4119. [PubMed: 6768748]
- Gorsky LD, Koop DR, Coon MJ. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction. *J Biol Chem* 1984;259:6812–6817. [PubMed: 6725272]
- Gruenke LD, Konopka K, Cadieu M, Waskell L. The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5. *J Biol Chem* 1995;270:24707–24718. [PubMed: 7559586]
- Hanna IH, Reed JR, Guengerich FP, Hollenberg PF. Expression of human cytochrome P450 2B6 in *Escherichia coli*: characterization of catalytic activity and expression levels in human liver. *Arch Biochem Biophys* 2000;376:206–216. [PubMed: 10729207]
- Hanna IH, Roberts ES, Hollenberg PF. Molecular basis for the differences in lidocaine binding and regioselectivity of oxidation by cytochromes P450 2B1 and 2B2. *Biochemistry* 1998;37:311–318. [PubMed: 9425052]
- Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. *Drug Metab Dispos* 2000;28:1176–1183. [PubMed: 10997936]
- Hildebrandt AG, Roots I, Tjoe M, Heinemeyer G. Hydrogen peroxide in hepatic microsomes. *Methods Enzymol* 1978;52:342–350. [PubMed: 672638]
- Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17- α -ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. *J Pharmacol Exp Ther* 2002;300:549–558. [PubMed: 11805216]
- Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. *Pharmacogenetics* 2001;11:399–415. [PubMed: 11470993]
- Oprian DD, Gorsky LD, Coon MJ. Properties of the oxygenated form of liver microsomal cytochrome P-450. *J Biol Chem* 1983;258:8684–8691. [PubMed: 6863307]
- Ortiz de Montellano PR. Arylhydrazines as probes of hemoprotein structure and function. *Biochimie* 1995;77:581–593. [PubMed: 8589069]
- Perret A, Pompon D. Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. *Biochemistry* 1998;37:11412–11424. [PubMed: 9708976]
- Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. *Drug Metab Dispos* 1999;27:655–666. [PubMed: 10348794]
- Schenkman JB, Jansson I. The many roles of cytochrome b5. *Pharmacol Ther* 2003;97:139–152. [PubMed: 12559387]
- Schrag ML, Wienkers LC. Topological alteration of the CYP3A4 active site by the divalent cation Mg (2+). *Drug Metab Dispos* 2000;28:1198–1201. [PubMed: 10997940]

- Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, Stout CD. An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. *Proc Natl Acad Sci U S A* 2003;100:13196–13201. [PubMed: 14563924]
- Scott EE, Spatzenegger M, Halpert JR. A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. *Arch Biochem Biophys* 2001;395:57–68. [PubMed: 11673866]
- Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-Å resolution: insight into the range of P450 conformations and the coordination of redox partner binding. *J Biol Chem* 2004;279:27294–27301. [PubMed: 15100217]
- Shebley M, Hollenberg PF. Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phenylcyclidine. *Drug Metab Dispos* 2007;35:1365–1371. [PubMed: 17460030]
- Sridar C, Harleton E, Hollenberg PF. Roles of the threonine 407, aspartic acid 417, and threonine 419 residues in P450 2B1 in metabolism. *Biochem Biophys Res Commun* 2005;338:386–393. [PubMed: 16157292]
- Swanson BA, Dutton DR, Lunetta JM, Yang CS, Ortiz de Montellano PR. The active sites of cytochromes P450 IA1, IIB1, IIB2, and IIE1. Topological analysis by in situ rearrangement of phenyl-iron complexes. *J Biol Chem* 1991;266:19258–19264. [PubMed: 1918043]
- Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. *Biochem Biophys Res Commun* 2004;319:1322–1326. [PubMed: 15194512]
- Tuck SF, Peterson JA, Ortiz de Montellano PR. Active site topologies of bacterial cytochromes P450101 (P450cam), P450108 (P450terp), and P450102 (P450BM-3). In situ rearrangement of their phenyl-iron complexes. *J Biol Chem* 1992;267:5614–5620. [PubMed: 1544935]
- Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. *Pharmacogenet Genomics* 2006;16:191–198. [PubMed: 16495778]
- Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. *J Pharmacol Exp Ther* 2003;306:287–300. [PubMed: 12676886]
- White RE, Coon MJ. Oxygen activation by cytochrome P-450. *Annu Rev Biochem* 1980;49:315–356. [PubMed: 6996566]
- Yamaguchi Y, Khan KK, He YA, He YQ, Halpert JR. Topological changes in the CYP3A4 active site probed with phenyldiazene: effect of interaction with NADPH-cytochrome P450 reductase and cytochrome b5 and of site-directed mutagenesis. *Drug Metab Dispos* 2004;32:155–161. [PubMed: 14709633]
- Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apocytochrome b5. *J Biol Chem* 1996;271:27438–27444. [PubMed: 8910324]
- Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, Yokoi T. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of *Escherichia coli*. *Protein Expr Purif* 2002;24:329–337. [PubMed: 11922748]
- Yamazaki H, Shimada T, Martin MV, Guengerich FP. Stimulation of cytochrome P450 reactions by apocytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. *J Biol Chem* 2001;276:30885–30891. [PubMed: 11413149]
- Zhang H, Gruenke L, Arscott D, Shen A, Kasper C, Harris DL, Glavanovich M, Johnson R, Waskell L. Determination of the rate of reduction of oxyferrous cytochrome P450 2B4 by 5-deazariboflavin adenine dinucleotide T491V cytochrome P450 reductase. *Biochemistry* 2003;42:11594–11603. [PubMed: 14529269]

Zhang H, Myshkin E, Waskell L. Role of cytochrome b5 in catalysis by cytochrome P450 2B4. *Biochem Biophys Res Commun* 2005;338:499–506. [PubMed: 16182240]

Figure 1.
Chemical structures of efavirenz and 17EE.

Figure 2. Formation of P450 2B6 N-phenylprotoporphyrin IX regioisomers

P450 2B6 was incubated with phenyldiazene and the phenyl-iron complex formation was observed spectrally as described under Materials and Methods. Oxidation caused migration of the phenyl to the porphyrin nitrogens. The individual peaks represent migration of the phenyl to pyrrole rings A (N_A), B (N_B), C (N_C) or D (N_D). Sample treatment and HPLC separation of the regioisomers were performed as described in Materials and Methods. The inset shows the heme structure with labeled pyrrole rings A, B, C and D. The chromatograms are representative of 3 separate experiments.

Figure 3. Formation of P450 2B6.4 *N*-phenylprotoporphyrin IX regioisomers

P450 2B6.4 was incubated with phenyldiazene and the phenyl-iron complex formation was observed spectrally as described under Materials and Methods. Oxidation caused migration of the phenyl to the porphyrin nitrogens. The individual peaks represent migration of the phenyl to pyrrole rings A (N_A), B (N_B), C (N_C) or D (N_D). Sample treatment and HPLC separation of the regioisomers were performed as described in Materials and Methods. The inset shows the heme structure with labeled pyrrole rings A, B, C and D. The chromatograms are representative of 3 separate experiments.

Figure 4. Inactivation of P450 2B6.4 by efavirenz in the presence of cytochrome b₅

The time- and concentration-dependent inactivation of P450 2B6.4 by efavirenz in the presence of cytochrome b₅ was measured by determining the 7-EFC *O*-deethylation activity. After initiation of reaction by the addition of NADPH, aliquots were removed from the primary reaction mixture at 0, 5, 10, 15 and 20 minutes. The concentrations of efavirenz were (■) 0 μM, (▼) 10 μM, (◆) 20 μM, (●) 40 μM, and (□) 50 μM. The data show the means and standard deviations from 4 separate experiments done in duplicate. In some cases the standard deviations were less than the size of the symbols. The inset shows the double reciprocal plot of the rates of inactivation as a function of the efavirenz concentrations.

Figure 5. Inactivation of P450 2B6.4 by 17EE in the presence of cytochrome b₅

The time- and concentration-dependent inactivation of P450 2B6.4 by 17EE was measured by determining the 7-EFC *O*-deethylation activity. After initiation of reaction by the addition of NADPH, aliquots were removed from the primary reaction mixture at 0, 5, 10, 15, and 20 minutes. The concentrations of efavirenz were (■) 0 μM, (◆) 40 μM, (●) 80 μM, (□) 120 μM and (▲) 160 μM. The data show the means and standard deviations from 4 separate experiments done in duplicate. In some cases the standard deviations were less than the size of the symbols. The inset shows the double reciprocal plot of the rates of inactivation as a function of the 17EE concentrations.

Figure 6. Metabolism of 17EE by P450 2B6.4 in the presence of cytochrome b₅

Metabolites A₁, A₂, and C are mono-hydroxylated metabolites, though the exact identities have not yet been determined. Metabolite D corresponds to 2-hydroxy-17EE, metabolite E corresponds to estrone. The parent compound, 17EE, is labeled. We previously showed that in the absence of cytochrome b₅ P450 2B6.4 does not readily metabolize 17EE (Bumpus et al., 2005).

Table 1**Inactivation of P450s 2B6 and 2B6.4 using *tert*-butylhydroperoxide to support the reaction**

P450s were incubated with *t*BHP and the inactivators indicated as described in the Materials and Methods section. Activity remaining was determined using the 7EFC *O*-deethylation assay. The data are presented as percent activity remaining as compared to a control sample incubated with *t*BHP in the absence of efavirenz or 17EE.

		Percent activity remaining	
		50 μ M inactivator	80 μ M inactivator
2B6	Efavirenz	52 $\pm$ 2	32 $\pm$ 1
2B6.4	Efavirenz	66 $\pm$ 3	48 $\pm$ 1
2B6	17EE	33 $\pm$ 1	21 $\pm$ 2
2B6.4	17EE	81 $\pm$ 4	70 $\pm$ 2

Stoichiometry for the metabolism of 17EE and efavirenz by P450s 2B6 and 2B6.4
P450s were reconstituted with reductase as described under Materials and Methods. NADPH oxidation was measured spectrally by monitoring absorbance at 340 nm. Portions of the sample were then used to determine hydrogen peroxide and product formation. Product formation was measured by substrate depletion. All of the values are presented as nmol/nmol P450/min.

P450	Substrate	NADPH oxidation	H ₂ O ₂ formed	Product formed	H ₂ O formed
2B6	No substrate	15.7±.5	2.2±.1	0	6.8
2B6	Efavirenz	16.2±.9	6.3±.1	6.8±.2	1.6
2B6	17EE	15.1±.6	7.8±.3	7.3±.4	0
2B6.4	No substrate	14.7±.6	7.2±.3	0	3.8
2B6.4	Efavirenz	16.3±.5	10.1±.4	3.8±.1	1.2
2B6.4	17EE	16.9±.4	12.6±.6	.78±.2	1.8

Improvement in P450 2B6.4 reaction coupling upon reconstitution with cytochrome b₅
P450s were reconstituted with reductase and cytochrome b₅ and the assays were performed as described under Materials and Methods.
NADPH oxidation was measured for 4 min then the sample was used to determine both hydrogen peroxide formation and product formation. All values are presented as nmol/nmol P450/min.

P450	Substrate	NADPH oxidation	H ₂ O ₂ formed	Product formed	H ₂ O formed
2B6	No substrate	14.3±4	1.8±2	0	6.3
2B6	Efavirenz	15.8±7	5.6±3	9.6±6	0.6
2B6	17EE	15.0±7	6.5±1	8.2±4	0.2
2B6.4	No substrate	13.1±2	5.1±1	0	4.0
2B6.4	Efavirenz	15.4±5	5.2±2	7.7±2	1.3
2B6.4	17EE	15.0±3	6.9±1	5.3±3	1.4